Koyfin Home > Directory > Health Care > Anika Therapeutics > Gross Margin

Anika Therapeutics Gross Margin Chart (ANIK)

Anika Therapeutics annual/quarterly Gross Margin from 2010 to 2020. Gross margin is a company's total sales revenue minus its cost of goods sold (COGS), divided by total sales revenue, expressed as a percentage. The higher the percentage, the more the company retains on each dollar of sales, to service its other costs and debt obligations.
  • Anika Therapeutics Gross Margin for the quarter ending June 06, 2020 was $51m a -56.82% decrease of -29m year over year
  • Anika Therapeutics Gross Margin for the last 12 months ending June 06, 2020 was $67m a -13.32% decrease of -9m year over year
  • Anika Therapeutics Annual Gross Margin for 2019 was $75m a 6.08% increase of 5m from 2018
  • Anika Therapeutics Annual Gross Margin for 2018 was $70m a -7.83% decrease of -6m from 2017
  • Anika Therapeutics Annual Gross Margin for 2017 was $76m a -1.17% decrease of -1m from 2016
Other Margins & Efficiency Metrics:
  • Anika Therapeutics EBITDA Margin for the quarter ending December 12, 2018 was $42m a 101.79% increase of 43m year over year
  • Anika Therapeutics Return on Capital % for the quarter ending December 12, 2018 was 9.41 a 116.45% increase of 10.95 year over year
  • Anika Therapeutics Return on Equity % for the quarter ending December 12, 2018 was 11.90 a 185.26% increase of 22.04 year over year
View Chart On Koyfin

Quarterly ANIK Gross Margin Data

06/2020$51m
03/2020$66m
12/2019$71m
09/2019$80m
06/2019$78m
03/2019$70m
12/2018$74m
09/2018$69m
06/2018$73m
03/2018$63m

Annual ANIK Gross Margin Data

2019$75m
2018$70m
2017$76m
2016$77m
2015$77m
2014$80m
2013$70m
2012$59m
2011$59m
2010$57m